Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Otolaryngology and Head & Neck Surgery
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2024

11.08.2023 | Original Article

Chemotherapy for Salivary Gland Malignant Carcinoma : Meta-analysis and Systemic Review

verfasst von: Kritant Bhushan, Mansi Luthra Sharma, Deepak Kumar Gupta

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

 The primary form of treatment for salivary gland cancer is surgical resection. Radiation therapy is used as adjuvant therapy in cases of aggressive tumours, currently patients with recurrent or metastatic cancer who are not suitable for surgery or radiation are most often treated with chemotherapy. PRISMA guidelines for systematic reviews were followed to evaluate salivary gland malignancies involving cytotoxic chemotherapy and biologic agents. An electronic literature search of Medline, PubMed, Scopus, etc. was performed and relevant articles were selected based on the inclusion criteria. Cytotoxic chemotherapies and biologic drugs such as anti HER − 2, anti-EGFR and anti-C-Kit are used to treat salivary gland cancer. Although most trials have respond poorly to standard chemotherapy with short durability and significant toxicity. Most of the research has focused on ACC and the use of combination therapy with cisplastin in conjunction with other treatments has been found to improve overall survival rate. Due to the limited patient population it was difficult to assess the efficacy of chemotherapy, which achieved very modest results. There are potential molecular targets such as HER2,NTRK and targeted treatments are becoming more popular. However to further explore potential treatment alternatives SGC patients should be enrolled in clinical trials.
Literatur
1.
Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC clinical trials group. Cancer 116(2):362–368PubMedCrossRef
2.
Airoldi M, Garzaro M, Pedani F, Ostellino O, Succo G, Riva G, Sensini M, Naqe N, Bellini E, Raimondo L et al (2014) Cisplatin + vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases. Am J Clin Oncol PMID:25089531
3.
Ross PJ, Teoh EM, A’Hern RP, Rhys-Evans PH, Harrington KJ, Nutting CM, Gore ME (2009) Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol) 21(4):311–314PubMedCrossRef
4.
Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH, Bang YJ (2015) Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer 121(15):2612–2617PubMedCrossRef
5.
Dillon PM, Petroni GR, Moskaluk C, Fracasso PM, Douvas MG, Perez JR, Varhegyi N, Zaja-Milatovic S, Thomas CY (2015) A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC). ASCO Meeting Abstr 33(15suppl):e17092
6.
Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT et al (2013) The mutational landscape of adenoid cystic carcinoma. Nat Genet 45(7):791–798PubMedPubMedCentralCrossRef
7.
Kim DW, Oh DY, Shin SH, Kang JH, Cho BC, Chung JS, Kim H, Park KU, Kwon JH, Han JY et al (2014) A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer 14:795PubMedPubMedCentralCrossRef
8.
Ho AL, Foster NR, Meyers JP, Deraje Vasudeva S, Katabi N, Antonescu CR, Pfister DG, Horvath LE, Erlichman C, Schwartz GK (2015) Alliance A091104: a phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma. ASCO Meeting Abstr 33(15suppl):6039
9.
Hoover AC, Milhem MM, Anderson CM, Sun W, Smith BJ, Hoffman HT, Buatti JM (2015) Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial. Head Neck 37(5):722–726PubMedCrossRef
10.
Goncalves PH, Kummar S, Siu LL, Hansen AR, Savvides P, Sukari A, Chao J, Heilbrun LK, Pilat MJ, Smith DW et al (2013) A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC). ASCO Meeting Abstr 31((15_suppl)):6045
11.
Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28(3):197–204PubMedCrossRef
12.
van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J et al (2008) Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 44(17):2542–2545PubMedCrossRef
13.
Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE (2001) Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111(8):1373–1378PubMedCrossRef
14.
Vered M, Braunstein E, Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24(7):632–636PubMedCrossRef
15.
Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45(7):574–578PubMedCrossRef
16.
Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR Jr (2015) Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck 37(5):644–649PubMedPubMedCentralCrossRef
17.
Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154(1):107–111PubMedCrossRef
18.
Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr (1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12(10):956–960PubMed
19.
Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E et al (2016) Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor- positive salivary gland cancers. Head Neck 38(5):724–731PubMedCrossRef
20.
Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, van der Slootweg PJ, van Herpen CM (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):e473–e476PubMedCrossRef
21.
Locati LD, Perrone F, Cortelazzi B, Imbimbo M, Bossi P, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L et al (2014) Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther 15(6):678–682PubMedPubMedCentralCrossRef
22.
Urban D, Rischin D, Angel C, D’Costa I, Solomon B (2015) Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw 13(3):288–290PubMedCrossRef
23.
Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24(17):2673–2678PubMedCrossRef
24.
Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, Molinari R (1996) Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7(6):640–642PubMedCrossRef
25.
Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D (1987) Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60(12):2869–2872PubMedCrossRef
26.
Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23(3):585–590PubMedCrossRef
27.
Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007) A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43(1):33–36PubMedCrossRef
28.
Guigay JM, Bidault F, Temam S, Janot F, Raymond E, Faivre S (2007) Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. ASCO Meeting Abstr 25(18suppl):6086
29.
Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF et al (2016) Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol 27(2):318–323PubMedCrossRef
30.
Ghosal N, Mais K, Shenjere P, Julyan P, Hastings D, Ward T, Ryder WD, Bruce I, Homer J, Slevin NJ (2011) Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 49(7):510–515PubMedCrossRef
31.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127PubMedCrossRef
32.
Hitre E, Budai B, Takacsi-Nagy Z, Rubovszky G, Toth E, Remenar E, Polgar C, Lang I (2013) Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 109(5):1117–1122PubMedPubMedCentralCrossRef
33.
Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fujii S (2016) Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol 114(1):36–43PubMedCrossRef
34.
Cohen RB, Delord J-P, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Cresta S, Hong R-L, Le Tourneau C et al (2016) Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. ASCO Meeting Abstr 34(15suppl):6017
35.
Giannoni C, el-Naggar AK, Ordonez NG, Tu ZN, Austin J, Luna MA, Batsakis JG (1995) c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg 112(3):391–398PubMed
36.
Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, Shreenivas AV, Tishler RB, Haddad RI (2013) Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 18(3):294–300PubMedPubMedCentralCrossRef
37.
Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39(7):724–727PubMedCrossRef
38.
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25(25):3978–3984PubMedCrossRef
39.
Guigay J, Fayette J, Even C, Cupissol D, Rolland F, Peyrade F, Laguerre B, Le Tourneau C, Zanetta S, Le Bozec L et al (2016) PACSA: phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC). ASCO Meeting Abstracts 34(15suppl):6086
40.
Kim Y, Lee SJ, Park K, Lee S-h, Sun JM, Keam B, An HJ, Cho JY, Kim J-S, Lee H-y et al (2016) Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: a multicenter phase II study. ASCO Meeting Abstr 34(15suppl):6090
41.
Ho AL, Sherman EJ, Baxi SS, Haque S, Ni A, Antonescu CR, Katabi N, Morris LG, Chan TA, Pfister DG (2016) Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. ASCO Meeting Abstr 34(15suppl):6096
Metadaten
Titel
Chemotherapy for Salivary Gland Malignant Carcinoma : Meta-analysis and Systemic Review
verfasst von
Kritant Bhushan
Mansi Luthra Sharma
Deepak Kumar Gupta
Publikationsdatum
11.08.2023
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 1/2024
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-023-04104-6

Weitere Artikel der Ausgabe 1/2024

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2024 Zur Ausgabe

Clinical Report

Adult T-cell Leukemia/Lymphoma (ATL) in the Nasal and Paranasal Cavity: Four Cases Report

Original Article

An Observational Study of Hearing Loss Among Menopausal Women

Original Article

Balloon Sinuplasty: Our Experience

Clinical Report

Diffuse Large B Cell Lymphoma of Lacrimal Drainage System : A Rare Case Report

Original Article

Enhancing Laryngeal Spinocellular Carcinoma Image Security with DCT

Clinical Report

Unusual intra-tracheal migration of a corrosive esophageal foreign body

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise